Gilead’s partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too restrictive. Key countries with rising HIV rates are excluded, and the control over the active pharmaceutical ingredient could delay price reductions. Patient groups are challenging Gilead’s patents globally, fearing the VL aims to maintain the company’s monopoly.
Related Posts
The dealmaker who took India global with a slew of big buys
Ratan Tata’s strategic acquisitions, starting with Tetley in 2000 for $432 million, transformed Tata Group into a global powerhouse. He orchestrated over 60 acquisitions, including […]
Why Indian Railways is unlikely to go for aluminium-bodied Vande Bharat trains
Indian Railways has nixed plans for aluminium-bodied Vande Bharat trains due to high costs and lack of domestic expertise. Future focus aims at cost-effective sleeper […]
PAN 2.0: Have an extra PAN Card? Surrender now to avoid Rs 10,000 penalty! Check steps
The Indian government has launched PAN 2.0, a program to modernize and digitize PAN and TAN administration. It will consolidate services, enhance security with QR […]